CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin

• Published in: Biomaterials research 2022-11, Vol.26 (1), p.1-64
• Main Authors: Ma, Jingbo, Xu, Xiaolong, Fu, Chunjin, Xia, Peng, Tian, Ming, Zheng, Liuhai, Chen, Kun, Liu, Xiaolian, Li, Yilei, Yu, Le, Zhu, Qinchang, Yu, Yangyang, Fan, Rongrong, Jiang, Haibo, Li, Zhifen, Yang, Chuanbin, Xu, Chengchao, Long, Ying, Wang, Jigang, Li, Zhijie
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Antibodies; Antigens; Biological products; Cadherin-17; Cadherins; Cancer; Cancer therapies; Cell survival; Chemotherapy; Drug delivery; Drug delivery systems; Drug resistance; Drugs; Embryos; Gastric cancer; Health aspects; Immunotoxin; Jingbo Ma, Xiaolong Xu and Chunjin Fu are contribute equally to this work and share the first-authorship; Libraries; Medical prognosis; Medicin och hälsovetenskap; Membrane proteins; Metastasis; Nanobodies; Nanobody; Phages; Prevention; Protein binding; Proteins; Stomach cancer; Targeted therapy; Tumors; Vehicles; Viral antibodies; Xenografts
• ISSN: 2055-7124; 1226-4601; 2055-7124
• DOI: 10.1186/s40824-022-00312-3

It is highly desirable to develop new therapeutic strategies for gastric cancer given the low survival rate despite improvement in the past decades. Cadherin 17 (CDH17) is a membrane protein highly expressed in cancers of digestive system. Nanobody represents a novel antibody format for cancer targeted imaging and drug delivery. Nanobody targeting CHD17 as an imaging probe and a delivery vehicle of toxin remains to be explored for its theragnostic potential in gastric cancer. Naïve nanobody phage library was screened against CDH17 Domain 1-3 and identified nanobodies were extensively characterized with various assays. Nanobodies labeled with imaging probe were tested in vitro and in vivo for gastric cancer detection. A CDH17 Nanobody fused with toxin PE38 was evaluated for gastric cancer inhibition in vitro and in vivo. Two nanobodies (A1 and E8) against human CDH17 with high affinity and high specificity were successfully obtained. These nanobodies could specifically bind to CDH17 protein and CDH17-positive gastric cancer cells. E8 nanobody as a lead was extensively determined for tumor imaging and drug delivery. It could efficiently co-localize with CDH17-positive gastric cancer cells in zebrafish embryos and rapidly visualize the tumor mass in mice within 3 h when conjugated with imaging dyes. E8 nanobody fused with toxin PE38 showed excellent anti-tumor effect and remarkably improved the mice survival in cell-derived (CDX) and patient-derived xenograft (PDX) models. The immunotoxin also enhanced the anti-tumor effect of clinical drug 5-Fluorouracil. The study presents a novel imaging and drug delivery strategy by targeting CDH17. CDH17 nanobody-based immunotoxin is potentially a promising therapeutic modality for clinical translation against gastric cancer.